Multimodality therapy for lung cancer invading the chest wall: A study of the French EPITHOR database.

Objectives: According to a nation-based study, we intend to report the data of the patients operated on for lung cancer invading the chest wall, taking into consideration the completion of induction chemotherapy (Ind_CT), induction radiochemotherapy (Ind_RCT) or no induction therapy (0_Ind).
Materials and Methods: All patients with a primary lung cancer invading the chest wall who underwent radical resection from 2004 to 2019 were included. Superior sulcus tumors were excluded.
Results: Overall, 688 patients were included: 522 operated without induction therapy, 101 with Ind&#95;CT and 65 with Ind&#95;RCT. Postoperative 90-day mortality was 10.7% in the 0&#95;Ind group, 5.0% in the Ind&#95;CT group, 7.7% in the Ind&#95;RCT group (p = 0.17). Incomplete resection rate was 14.0% in the 0&#95;Ind group, 6.9% in the Ind&#95;CT group, 6.2% in the Ind&#95;RCT group (p = 0.04). In the 0&#95;Ind group, 70% of the patients received adjuvant therapies. Overall survival (OS) analysis disclosed the best long-term outcomes in the Ind&#95;RCT group (5-year OS probability: 56.5% versus 40.0% and 40.5% for 0&#95;Ind and Ind&#95;CT groups, respectively; p = 0.035). At multivariable analysis, Ind&#95;RCT (HR = 0.571; p = 0.008), age > 60 years old (HR = 1,373; p = 0.005), male sex (HR = 1.710; p < 0.001), pneumonectomy (HR = 1.368; p = 0.025), pN2 status (HR = 1.981; p < 0.001), ≥3 resected ribs (HR = 1.329; p = 0.019), incomplete resection (HR = 2.284; p < 0.001) and lack of adjuvant therapy (HR = 1.959; p < 0.001) were associated with OS. Ind&#95;CT was not associated with survival (HR = 0.848; p = 0.257).
Conclusion: Induction chemoradiation therapy seems to improve survival. Therefore, the present results should be confirmed by a prospective randomized trial testing the benefit of induction radiochemotherapy for NSCLC invading the chest wall.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier B.V. All rights reserved.)